A5033613047- Psoriasis: Treatment and Pathogenesis
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Migraine and Headache Studies
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- Workplace Health and Well-being
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Immunodeficiency and Autoimmune Disorders
- Sleep and related disorders
- Biosimilars and Bioanalytical Methods
- Lung Cancer Research Studies
- Sleep and Work-Related Fatigue
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Breast Cancer Treatment Studies
- Head and Neck Cancer Studies
- Cancer Genomics and Diagnostics
- Medication Adherence and Compliance
- Wnt/β-catenin signaling in development and cancer
- Therapeutic Uses of Natural Elements
- Inflammatory Bowel Disease
Janssen Scientific Affairs (United States)
2019-2025
Janssen (United States)
2019-2025
Johnson & Johnson (United States)
2024-2025
Janssen (Belgium)
2020-2024
St. Vincent's University Hospital
2024
Tufts University
2018-2023
Maine Medical Center
2018-2023
Ridgeview
2022
Janssen (Switzerland)
2020
Maine Medical Center
2018-2019
Context: Insomnia is a common and seriously impairing condition that often goes unrecognized.Objectives: To examine associations of broadly defined insomnia (ie, meeting inclusion criteria for diagnosis from International Statistical Classification Diseases, 10th Revision, DSM-IV, or Research Diagnostic Criteria/International Sleep Disorders, Second Edition) with costly workplace accidents errors after excluding other chronic conditions among workers in the America Survey...
To estimate associations of broadly defined insomnia (i.e., meeting inclusion criteria for International Classification Diseases, Tenth Revision (ICD-10), Diagnostic and Statistical Manual Mental Disorders, Fourth Edition (DSM-IV), or Research Criteria/International Sleep Second (RDC/ICSD-2) diagnosis) with workplace/nonworkplace injuries controlling comorbid conditions among workers in the America Insomnia Survey (AIS).Cross-sectional telephone survey.National sample 4,991 employed health...
To examine the disability, health care resource utilization, and direct annual costs among patients with migraine, categorized according to number of headache days experienced in past month.Migraine exists on a continuum different attack frequencies associated levels disability. People migraine have increased utilization incur substantially more than those without disease. While broad implications are evident, there is need comprehensively describe impact frequency burden illness.Data from...
Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss efficacy may occur over time, requiring switching or escalation. Claims data on persistence be informative real-world outcome. This analysis described and rates remission patients with psoriasis initiated current biologics.Adults (index date) guselkumab, adalimumab, secukinumab, ixekizumab between 07/13/2017 07/31/2020 were identified in IBM MarketScan Databases. Discontinuation (or end...
Psoriasis (PsO) is a common dermatological condition. severity commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for knowledge of clinical practice patterns in patients PsO are limited. Here, we use real-world data to characterize diagnosed their management. Data were derived from the Adelphi Real World Disease Specific Programme™, cross-sectional survey dermatologists adult USA, between...
Introduction: The efficacy and real-world treatment persistence of guselkumab (GUS) has been shown to be superior other advanced options [1,2] for psoriasis (PsO); however, long-term effectiveness vs. biologic therapies warrants further study. Therefore, this study compared the GUS with adalimumab (ADA), ixekizumab (IXE), secukinumab (SEC), ustekinumab (UST) in PsO patients through 30 months follow-up. Methods: An active comparator, new-user design was used compare initiators each comparator...
The National Clinical Programme for Rheumatology pilot project Work-Able Solutions is an integrated care occupational therapy vocational rehabilitation service people with musculoskeletal disorders and arthritis. Funded by the Sláintecare Integration Innovation Fund (2022) this delivering services across Dublin South, Wicklow, Kildare, Waterford until December 2024. Two sites are based in acute hospital setting (St Vincent’s University Hospital Naas General Hospital) outward into primary...
Abstract Background/Aims Treat to target strategies of inflammatory arthritis primarily focuses on pharmacological management. We introduced the assessment lifestyle alongside composite scores disease activity aiming for patients achieve optimal health and promote patient centred care. Lifestyle can influence treatment options course in particular physical levels, obesity, smoking, stress alcohol use. Health professionals have opportunity early stages include discussion about clinical...
Study Objective. To measure the association of symptoms attributed to residual effects sleep medication (e.g., drowsiness, difficulty concentrating, and impaired memory) on self-reported functioning satisfaction with these medications. Methods. Individuals using prescription medications for insomnia were invited complete an Internet-based survey. Respondents compared according presence effects; relationships between severity outcomes modeled regression. Measures included Brief Insomnia...
In this US-based study of the National Cancer Database (NCDB), we examined 8550 patients diagnosed with non-metastatic, invasive inflammatory breast cancer (IBC) who received surgery from 2004–2013. Patients were grouped into four biologic subtypes (HR+/HER2−, HR+/HER2+, HR−/HER2+, HR−/HER2−). On average, women 56 years age at diagnosis and followed for a median 3.7 years. The majority white (80%), had private health insurance (50%), presented poorly differentiated tumors (57%)....
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in sequential phase I/II trial unselected patients with refractory advanced non-small-cell lung cancer (NSCLC).The I determined recommended dose dalotuzumab at 5 mg/kg or 10 weekly 20 patients. The II compared outcomes to alone established trial. Erlotinib 150 mg was safe. included 37 arm 38 arm. Progression-free survival 1.6...
Adalimumab (ADA), certolizumab pegol (CER), etanercept (ETA), guselkumab (GUS), ixekizumab (IXE), secukinumab (SEC), and ustekinumab (UST) are biologics approved for the treatment of psoriasis (PsO) psoriatic arthritis (PsA). We examined adherence persistence among PsO patients with comorbid PsA who initiated any these biologics.Adult ≥1 pharmacy/medical claim seven biologics, diagnosis both were selected from MarketScan Commercial database (July 2014-June 2019). Adherence rates study...
Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence remission among patients initiating guselkumab versus inhibitors.
Objectives: To assess long-term (2-year) biologic treatment patterns of psoriatic arthritis (PsA) patients who initiated adalimumab, certolizumab pegol, etanercept, golimumab, or ustekinumab.Methods: Adult with ≥1 pharmacy medical claim for injectable PsA biologics (index date) were identified from the Optum's Clinformatics Data Mart (1 January 2013-31 December 2016). Adherence, persistence, post-discontinuation patterns, and addition adjunctive medications evaluated by index...
Objective: To compare switching and discontinuation patterns of patients stable on originator infliximab (IFX) who switched to an IFX biosimilar (switchers) or remained (continuers) in the United States. Methods: Symphony Health Solutions' Patient Transactional Datasets (10/2012– 03/2019) were used identify adults with ≥ 2 claims for either rheumatoid arthritis (RA), psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease (IBD); 1 claim IFX. The index date...
BACKGROUND: Days supply values reported in large administrative claims databases are commonly used to estimate drug exposure and quantify adherence persistence with prescribed therapy. In recent database studies assessing treatment patterns for biologic therapies, a high frequency of 28-31-days has been observed therapies label-recommended maintenance dosing intervals longer than 4 weeks. Such inconsistencies suggest potential inaccuracy days data. OBJECTIVE: To confirm the existence...
Adalimumab (ADA), certolizumab pegol (CER), etanercept (ETA), guselkumab (GUS), ixekizumab (IXE), secukinumab (SEC), and ustekinumab (UST) are biologic medications approved in the USA for treatment of moderate to severe psoriasis. We examined drug adherence persistence patients with psoriasis who initiated these seven medications.Adult ≥1 pharmacy/medical claim any diagnosis previous 6 months between July 1, 2014 June 30, 2019 were selected from IBM MarketScan® Commercial Claims Encounters...
Biologics are a standard therapy for patients with moderate-to-severe psoriasis, yet treatment persistence is essential to achieve disease control. Compared other biologics, ustekinumab has been associated lower rates of discontinuation and better adherence among but prior studies have included limited data from the period after approval self-administration ustekinumab. This study was conducted assess risk plaque psoriasis initiating or biologics. Adults one more claim ustekinumab,...
In clinical trials, treatment with the interleukin-23 inhibitor guselkumab was associated significantly improved disease severity and patient-reported outcome measures (PROMs) among patients moderate-to-severe plaque psoriasis. However, limited information is available regarding real-world effectiveness of psoriasis mild, moderate, severe Investigator's Global Assessment (IGA) severities living in USA Canada. Patients participating CorEvitas Psoriasis Registry between 18 July 2017 10 2019...
Psoriasis is a chronic autoimmune disease that associated with substantial economic burden related to work productivity loss (WPL). WPL commonly measured using the Work Productivity and Activity Impairment (WPAI) questionnaire. However, WPAI does not measure outcomes among unemployed patients, may therefore underestimate of psoriasis. This study evaluated relationship between Dermatology Life Quality Index (DLQI) questionnaire work/study domain WPAI, as DLQI assesses impact psoriasis on...
The aim of this study was to examine pathologic complete response (pCR) and overall survival (OS) patients diagnosed with non-metastatic inflammatory breast cancer (IBC). A total N=8,550 cases undergoing surgery were identified between 2004-2013, using the National Cancer Database (NCDB). Patients grouped into 4 biologic subtypes (HR+/HER2-, HR+/HER2+, HR-/HER2+, HR-/HER2-). median age at diagnosis 56 years. On average, women followed for 3.7 years [interquartile range=3.0]. majority white...